Embodiments of the present invention generally relate to therapeutic treatment systems, and more particularly, to methods and systems for generating thermal bubbles for improved ultrasound imaging and therapy.
Ultrasound has long been used for diagnostic imaging applications. More recently however, several new therapeutic applications for ultrasound are being discovered.
Various embodiments of the present invention provide a method and system uniquely capable of generating thermal bubbles for improved ultrasound imaging and therapy.
In various embodiments, the physical mechanisms for generating thermal bubbles can comprise one or more of the following: (1) selective absorption of ultrasound energy within a bubbly medium due to enhanced attenuation from scattering; (2) enhanced thermal gradient in a micro-bubble rich region due to enhanced viscous losses from stable cavitation; (3) enhanced thermal response due to ultrasound-gas-vapor voids; and (4) enhanced deposition of thermal energy from inertial cavitation events.
In various embodiments, providing ultrasound energy to cell membranes or tissues with thermal bubbles ultrasound imaging and therapy. For example, in various embodiments, the permeability and/or transparency of cell membranes can be modulated. For example, in some embodiments, the permeability and/or transparency of cell membranes is increased. In some embodiments, heating can cause better diffusion of a material or a drug through the layers of skin tissue. Cavitation and radiation force involves sustained oscillatory motion of bubbles (a.k.a. stable cavitation) and/or rapid growth and collapse of bubbles (a.k.a. inertial cavitation). Resulting fluid velocities, shear forces and shock waves can disrupt cell membranes or tissues and induce chemical changes in the surrounding medium. The collapse of bubbles can additionally increase the bubble core temperature and induce chemical changes in the medium (e.g., generate highly reactive species, such as free radicals). Each of the above effects can impact ultrasound imaging and therapy effectiveness. In addition, other ways to impact ultrasound imaging and therapy include melting or mechanically disrupting thermally sensitive or mechanically fragile substances, such as medicant-carrying liposomes and/or other chemical loaded, gas or liquid filled stabilized spheres, analogous to local delivery.
In some embodiments, ultrasound imaging and therapy can be enhanced when shock waves generated upon collapse of bubbles disrupt the stratum corneum and thereby enhance skin permeability. Likewise, ultrasound imaging and therapy effectiveness can be enhanced when shock waves transiently compromise the integrity of cell membranes or tissues, or when local free-radical concentration enhances medicant toxicity. Moreover, certain medicants can be activated and/or released using energy. In that regard, a medicant encapsulated in a carrier can be released at the site of interest using energy (e.g., acoustic energy). For example, U.S. Pat. No. 6,623,430, entitled “Method and Apparatus for Safely Delivering Medicants to a Region of Tissue Using Imaging, Therapy and Temperature Monitoring Ultrasonic System”, which is hereby incorporated by reference in its entirety.
In various embodiments, a region of interest (or “ROI”) is located within one of the nonviable epidermis (i.e., the stratum corneum), the viable epidermis, the dermis, the subcutaneous connective tissue and fat, and the muscle. Depths may be in the range of about 0 mm to about 3 mm, 5 mm, 8 mm, 10 mm, 25 mm, 60 mm, 80 mm, or 100 mm or more. In accordance with various embodiments, the ROT is located about 20 mm to about 30 mm below the stratum corneum. Further, a plurality of ROI can be treated, and in some embodiments, simultaneously. For example, the ROI may consist of one or more organs or a combination of tissues either superficial or deep within the body.
In various embodiments, the method and system is uniquely capable of disrupting cell membranes or tissues and inducing chemical changes in the surrounding medium at either a single or multiple layers of skin tissue simultaneously (e.g., a plurality of depths within a cell membrane or tissue simultaneously). For example, in one embodiment, one frequency of acoustic energy at one skin layer might generate shock waves upon collapse of bubbles to disrupt the stratum corneum and thereby enhance skin permeability. A different frequency of acoustic energy at a different skin layer might simply provide heat to cause better diffusion of medicants through the layers of skin tissue. Yet another frequency of acoustic energy at a different skin layer might compromise the integrity of cell membranes or tissues, or generate local free-radicals to enhance or reduce medicant toxicity. In various embodiments, acoustic energy can be deposited in three-dimensions and at variable depths to selectively increase tissue permeability to thereby steer or guide the medicant through the tissue to a region of interest.
In various embodiments, the methods and systems disclosed herein contemplate the use of unfocused, focused, or defocused acoustic energy at variable spatial and/or temporal energy settings, in the range of about 1 kHz-100 MHz (e.g. about 1 kHz-50 kHz, 50 kHz-100 kHz, 100 kHz-500 kHz, 500 kHz-1 MHz, 3 MHz-7 MHz, 1 MHz-20 MHz, 1 MHz-10 MHz, 10 MHz-50 MHz, and/or 50 MHz-100 MHz, and any ranges or combinations of ranges), and at variable tissue depths. In various embodiments, the tissue depth can include, but are not limited to, 0-1 mm, 1 mm-2 mm, 2 mm-3 mm, 3 mm-4 mm, 4 mm-5 mm, 5 mm-6 mm, 6 mm-7 mm, 7 mm-8 mm, and 8 mm or more, and any ranges or combinations of ranges. The unique ability to customize acoustic energy output and target a particular region of interest makes possible highly accurate and precise thermal bubble formation.
In various embodiments, a system comprises a probe, a control system, and a display or indicator system. The probe can comprise various probe and/or transducer configurations, In various embodiments, the probe delivers unfocused, focused, or defocused ultrasound energy to the region of interest. Imaging and/or monitoring may alternatively be coupled and/or co-housed with a system contemplated by embodiments of the present invention.
In various embodiments, the control system and display system can also optionally comprise various configurations for controlling probe and system functionality, including for example, a microprocessor with software and a plurality of input/output devices, a system for controlling electronic and/or mechanical scanning and/or multiplexing of transducers, a system for power delivery, systems fir monitoring, systems for sensing the spatial position of the probe and/or transducers, and systems for handling user input and recording treatment results, among others.
In various embodiments, a system for generating thermal bubbles for improved ultrasound imaging and therapy includes a control system configured for control of the system, a probe configured for generating thermal bubbles, and a display system.
In various embodiments, a system for imaging thermal bubbles includes a control system configured for control of the system, a probe configured for imaging thermal bubbles, and a display system.
In various embodiments, a method for generating thermal bubbles for improved ultrasound imaging and therapy includes the steps of providing a source of acoustic energy, coupling the acoustic energy to a region of interest, and focusing the acoustic energy to the region of interest to generate thermal bubbles, wherein the source frequency of the acoustic energy is in the range of about 10 kHz to about 30 MHz.
In various embodiments, a method for generating thermal bubbles to evoke a cellular response includes the steps of providing a source of acoustic energy, coupling the acoustic energy to a region of interest; and focusing the acoustic energy to the region of interest to generate thermal bubbles, wherein the source frequency of the acoustic energy is in the range of about 10 kHz to about 30 MHz (e.g., about 10 kHz-50 kHz, 50 kHz-100 kHz, 100 kHz-500 kHz, 500 kHz-1 MHz, 1 MHz-10 MHz, and/or 10 MHz-30 MHz or overlapping ranges therein), and evoking a cellular response. In various embodiments the cellular response comprises one or more of a wound healing response, an immune histological response, heat-shock protein expression, programmed cell death, wound debridement, keloid/scar healing, and increased localized micro-circulation.
In various embodiments, a method for generating thermal bubbles to affect a chemical moiety includes the steps of providing a source of acoustic energy, coupling the acoustic energy to a region of interest; and focusing the acoustic energy to the region of interest to generate thermal bubbles, wherein the source frequency of the acoustic energy is in the range of about 10 kHz to about 30 MHz (e.g., about 10 kHz-50 kHz, 50 kHz-100 kHz, 100 kHz-500 kHz, 500 kHz-1 MHz, 1 MHz-10 MHz, and/or 10 MHz-30 MHz, or overlapping ranges therein) and evoking an effect on a chemical moiety. In various embodiments, the effect includes enhancing the delivery or augmenting the activation of the chemical moiety.
In various embodiments, a method for optimization of therapy includes concomitant monitoring of bubble activity by monitoring (a) one or more non-thermal responses, (b) one or more thermal responses and/or (c) one or more tissue property changes.
In several embodiments, the systems (and methods thereof) comprise the use of thermal bubbles in which the source frequency of the acoustic energy is about 1-10 MHz for therapy (e.g., 4 or 7 MHz) and 5-25 MHz for imaging (e.g., 18 MHz).
The subject matter of various embodiments of the invention is particularly pointed out in the claims. Various embodiments of the invention, both as to organization and method of operation, may be understood by reference to the following description taken in conjunction with the accompanying drawing figures, in which like parts may be referred to by like numerals, and:
Several embodiments of the present invention may be described herein in terms of various functional components and processing steps. It should be appreciated that such components and steps may be realized by any number of hardware components configured to perform the specified functions and processes. For example, various embodiments of the present invention may employ various medical treatment devices, visual imaging and display devices, input terminals and the like, which may carry out a variety of functions and processes under the control of one or more control systems or other control devices. In addition, various embodiments of the present invention may be practiced in any number of medical contexts and the embodiments relating to a method and system for generating thermal bubbles for improved ultrasound imaging and therapy, as described herein, are merely indicative of embodiments of applications for the invention. For example, the principles, features and methods discussed may be applied to any medical application. Further, various aspects of embodiments of the present invention may be suitably applied to other applications.
In various embodiments of systems, and as illustrated in
Each one of these mechanisms can be modulated either individually or used in combination with a thermal tissue effect. In various embodiments, the source frequency is between 1 kHz-100 MHz, 5 kHz-50 MHz, and/or 10 kHz-30 MHz (e.g., about 1 kHz-50 kHz, 50 kHz-100 kHz, 100 kHz-500 kHz, 500 kHz-1 MHz, 1 MHz-10 MHz, and/or 10 MHz-30 MHz, or overlapping ranges therein).
In various embodiments, the activation source powers are dependent on the frequency, bubble size distribution, bubble density and tissue. For example, in some embodiments, the lower the frequency, the less intense field is required to initiate thermal bubble activity. In some embodiments, the higher the nominal bubble size, the lower the source frequency at which the gas bodies will resonate. In some embodiments, the higher the local concentration of gas bodies, the greater effect with thermal bubbles can be achieved.
A wide range of transducer design configurations are used in accordance with several embodiments, as further discussed below. These thermal bubble effects can also be leveraged to augmented imaging and treatment monitoring.
The methods and systems according to several embodiments disclosed herein contemplate the use of unfocused, focused, or defocused acoustic energy at variable spatial and/or temporal energy settings, in the range of about 1 kHz-100 MHz (e.g., about 1 kHz-50 kHz, 50 kHz-100 kHz, 100 kHz-500 kHz, 500 kHz-1 MHz, 1 MHz-10 MHz, 10 MHz-30 MHz, and/or 30 MHz-100 MHz, or overlapping ranges therein), and at variable tissue depths. The unique ability to customize acoustic energy output and target a particular region of interest makes possible highly accurate and precise thermal bubble formation.
In several embodiments, the energy is acoustic energy. In other embodiments, the energy is photon based energy (e.g., IPL, LED, laser, white light, etc., or combinations thereof), or other energy forms, such radio frequency electric currents (including monopolar and bipolar radio-frequency current). In an embodiment, the energy is various combinations of acoustic energy, photon based energy, electromagnetic energy and other energy forms or energy absorbers such as cooling.
One or more of a transducer and/or transduction element configuration, a lens, and mechanical movement of a transducer may facilitate targeting of a particular region of interest and/or thermal bubble formation at specific locations.
In accordance with a method according to several embodiments, thermal bubbles act as contrast agents (e.g., markers or boundaries) for ultrasound imaging and therapy. In this manner, a region of interest can be marked or defined such that acoustic energy can be locally applied at for example, a cell, tissue, gland, fiber, or tumor. A boundary can be in any two-dimensional or three-dimensional configuration suitable for defining a region of interest for acoustic energy deposition (e.g., circle, square, triangle, sphere, cube, cone, or any arbitrary shape). The acoustic energy deposited therein may be for any therapeutic purpose now known or later devised (e.g., for ablative or non-ablative purposes).
In accordance with another method, just as thermal bubbles are used as boundaries for acoustic energy inclusion, as described herein, thermal bubbles can be used as boundaries for acoustic energy exclusion. In other words, thermal bubbles can be used to protect or to avoid various cells, tissues, glands, fibers, and/or regions of even higher acoustic impedance or sensitivity, for example. In some embodiments, bubbles are used to partially or fully isolate a region of interest.
Because thermal bubbles exhibit high acoustic impedance, in accordance with some embodiments of a method, they are used to concentrate acoustic energy deposition within a region of interest. For example, thermal bubbles may be created in such a manner so as to “funnel” acoustic energy as it moves from the energy source to the region of interest, thereby concentrating acoustic energy at the deposition site. An acoustical impedance mismatch can be created between the thermal bubble and the surround tissue. This acoustical mismatch can cause acoustic energy traveling through tissue to reflect, deflect, and/or scatter upon contact with the thermal bubble.
In various embodiments, a method of providing non-invasive ultrasound treatment, can comprise coupling an acoustic source to a surface of skin; providing a first acoustic energy into a region of interest below the surface; creating thermal bubbles in a first portion of the region of interest; providing a second acoustic energy into a second portion of the region of interest; and stimulating a bio-effect in the second portion of the region of interest.
In one embodiment, the method can comprise forming a boundary comprising the thermal bubbles. In one embodiment, the method can comprise reflecting a portion of the second acoustic energy off of at least one of the thermal bubbles. In one embodiment, the method can comprise directing the portion of the second portion of the second acoustic energy away from tissue outside of the region of interest from the second acoustic energy. In one embodiment, the method can comprise protecting the tissue outside of the region of interest from the second acoustic energy. In one embodiment, the tissue outside of the region of interest comprises an internal organ. In one embodiment, the method can comprise directing the portion of the second portion of the second acoustic energy into the second portion of the region of interest.
In one embodiment, the method can comprise scattering at least a portion of the second acoustic energy. In one embodiment, the method can comprise concentrating the second acoustic energy into the second portion of the region of interest. In one embodiment, the method can comprise controlling a size of the thermal bubbles. In one embodiment, the method can comprise increasing a temperature of the first portion of the region of interest. In one embodiment, the method can comprise controlling a size of the thermal bubbles. In one embodiment, the method can comprise surrounding the second portion of the region of interest with the boundary.
In one embodiment, the method can comprise creating a thermal lesion in the second portion of the region of interest. In one embodiment, the method can comprise cosmetically enhancing the skin. In one embodiment, the method can comprise treating the region of interest. In one embodiment, the method the stimulating a bio-effect in the second portion of the region of interest is reducing a volume of tissue. In one embodiment, the method can comprise tightening a portion of the surface of the skin. In one embodiment, the method can comprise providing a third acoustic energy to region of interest. In one embodiment, the method can comprise stimulating a second bio-effect in the region of interest.
In various embodiments, a method of cosmetic enhancement can comprise coupling at least one source to a region of interest; directing a first energy into the region of interest; creating a plurality of thermal bubbles in at least one of the region of interest and a non-target region; directing a second energy into the region of interest; and enhancing at least a portion of the region of interest.
In one embodiment, the at least one source comprises an ultrasound source and a pulsed laser. In one embodiment, the first energy is at least one of photon based energy and ultrasound energy. In one embodiment, the second energy is at least one of photon based energy and ultrasound energy. In one embodiment, the method can further comprise ablating tissue in the region of interest.
In one embodiment, the method can comprise tightening skin on a surface of the region of interest. In one embodiment, the method can comprise introducing a chemical moiety configured to enhance the creating the plurality of thermal bubbles. In one embodiment, the method can comprise imaging at least a portion of the region of interest. In one embodiment, the method can comprise locating the plurality of thermal bubbles. In one embodiment, the method can comprise reflecting the second energy off of at least one of the thermal bubbles.
In various embodiments, a method of treating tissue can comprise providing a first energy into a region of interest; creating at least one thermal bubble in the region of interest; providing a second energy into the region of interest; modulating the second energy; and controlling a size of the at least one thermal bubble.
In one embodiment, the method can comprise increasing the size of the at least one thermal bubble. In one embodiment, the method can comprise oscillating between a first size and a second size of the at least one thermal bubble. In one embodiment, the method can comprise stimulating a bio-effect in the region of interest. In one embodiment, the method can comprise inserting a plurality of bubbles into the region of interest. In one embodiment, the method can comprise increasing a temperature within the region of interest. In one embodiment, the method can comprise stimulating a therapeutic effect within the region of interest. In one embodiment, the method can comprise providing a third energy into the region of interest. In one embodiment, the method can comprise thermally injuring a portion of tissue in the region of interest. In one embodiment, the method can comprise cosmetically enhancing at least a portion of the region of interest.
In accordance with some methods, thermal bubbles are also particularly useful in preferential heating applications. For example, various cells, tissues, glands, fibers, and tumors can be either directly or indirectly therapeutically benefited by increases in temperature. And various therapeutic treatments, such as drug delivery, are facilitated by increases in temperature. Heating applications may be carried out alone or in combination with other thermal bubble applications and/or ultrasound imaging or therapy.
As mentioned above, collapse of cavitation bubbles can generate shock waves capable of disrupting cells and tissues and can induce chemical changes in the surrounding medium (e.g., generate highly reactive species, such as free radicals). Because some embodiments of the present invention enable highly accurate and precise thermal bubble formation, cells, tissues, glands, fibers, tumors, etc, can be selectively disrupted to accomplish various therapeutic applications, and various chemical changes can be induced at specific locations.
As noted above, each one of the abovementioned thermal bubble mechanisms can be modulated either individually or used in combination with a thermal tissue effect. In various embodiments, the combination effect of thermal tissue effects with the use of thermal bubbles effectuates and/or modulates a tissue response. In embodiments, use of bubble effects (inter-intracellular shear with a thermal tissue effect, e.g., thermal gradient), activates a wound healing response, an immune histological response, heat-shock protein expression and/or programmed cell death. In embodiments, tissue responses comprise wound debridement, keloid/scar healing, and increased localized micro-circulation.
In some embodiments, the thermal bubble response is maximized with the concomitant use of micro-bubble based formulations, emulsifiers, saponificants and/or emulsions. Thermal bubble use with other chemical moieties (e.g., analgesics, topical anesthetics, antibiotics, antibacterials, antimicrobials retinoids, etc.) may be useful to (1) enhance their delivery and/or (2) to augment their activation.
In some embodiments, selective tissue effects are achieved with a selective thermal-bubble response within one or more tissues (such as deep dermis, subcutaneous layers, etc). In other embodiments, selective tissue responses are enhanced within one or more glandular structures (such as sebaceous gland, sweat gland, hair follicle, etc.), by initiating a localized resonant cavity effect.
In accordance with some embodiments, optimization of therapy is accomplished using concomitant monitoring of bubble activity, for example, monitoring (a) one or more non-thermal responses (e.g., shear, inertial cavitation), (b) one or more thermal responses (e.g., vaporization) and/or (c) one or more tissue property changes. In accordance with one aspect of an embodiment, monitoring of bubble activity comprises imaging.
In various embodiments, the methods and systems for generating thermal bubbles for improved ultrasound imaging and therapy comprise delivering energy to a region of interest (“ROI”) within one or more layers of tissue. As mentioned above, in an embodiment, the energy is acoustic energy. In other embodiments, the energy is photon based energy (e.g., IPL, LED, laser, white light, etc.), or other energy forms, such radio frequency electric currents (including monopolar and bipolar radio-frequency current). In an embodiment, the energy is various combinations of acoustic energy, photon-based energy, electromagnetic energy and other energy forms or energy absorbers such as cooling.
In various embodiments, systems and/or methods are configured to produce one or more bio-effects. The term “bio-effects”, as used herein, shall be given its ordinary meaning and shall also mean biological effects and include, but not be limited to, effects on tissue (including in vivo, in vitro, in situ and ex vivo tissue), cells, organs and other body parts. Bio-effects include, but are not limited to, incapacitating, partially incapacitating, severing, rejuvenating, removing, ablating, micro-ablating, shortening, manipulating, or removing tissue either instantly or over time, and/or other effects, and/or combinations thereof. Bio-effects include, but are not limited to, tissue manipulation to e.g., facilitate aesthetic effects. Bio-effects also include, but are not limited to, tissue manipulation to e.g., enhance collagen formation or healing. Various bio-effects are further disclosed in U.S. patent application Ser. No. 11/857,989 filed Sep. 19, 2007, published as US2008/0071255, which is incorporated in its entirety by reference, herein. In various embodiments, treatment of a specific subcutaneous tissue to achieve a desired bio-effect uses ultrasound energy from system that may be directed to a specific depth within ROI to reach the targeted subcutaneous tissue. In one embodiment, a bio-effect is cutting tissue. In one embodiment, for example, if it is desired to cut muscle (by applying ultrasound energy at ablative levels), which is a distance below the surface of the skin, ultrasound energy from ultrasound system may be provided at ROI at a level to reach above, below, or approximately at the distance targeted at an ablative level which may be capable of ablating muscle.
In various embodiments, bio-effects may produce a clinical outcome such as a brow lift which can comprise elevating the patient's eyebrows and reducing wrinkles on the patient's brow or forehead region. In some embodiments, the clinical outcome may be the same or similar to traditional invasive surgery techniques, and may comprise the removal of wrinkles through a brow lift or replacement of treatment muscles and/or other tissue and subcutaneous tissue within the forehead (or other regions on the body) with muscle relaxant drugs.
In various embodiments, wrinkles can be partially or completely removed by applying ultrasound energy at ROI along the patient's forehead at levels causing the desired bio-effects. In various embodiments, bio-effects can comprise ablating, micro-ablating, coagulating, severing, partially incapacitating, shortening, removing, or otherwise manipulating tissue or subcutaneous tissue to achieve the desired effect. In various embodiments, method can be used to ablate, micro-ablate, or coagulate a specific tissue, or can be used as part of removing the subcutaneous tissue. Further, in one embodiment, muscle (such as the corrugator supercilii muscle) can be paralyzed and permanently disabled.
In various embodiments, systems and/or methods are configured to initiate and/or stimulate one or more biological responses. In various embodiments, biological responses can comprise, but are not limited to, diathermy, hemostasis, revascularization, angiogenesis, growth of interconnective tissue, tissue reformation, ablation of existing tissue, protein synthesis and/or enhanced cell permeability. Two or more of these biological responses may be combined to facilitate rejuvenation and/or treatment of superficial tissue. In various embodiments, responses to embodiments of systems or embodiments of methods are initiated and/or stimulated by effects can include any biological response initiated and/or stimulated by energy effects, such as, for example: 1) hemostasis, including that stimulated from concentrated ultrasound, 2) subsequent revascularization/angiogenesis, such as that generated from high frequency applications of approximately 2 MHz to 7 MHz or more, 3) growth of interconnective tissue, 4) reformation and/or ablation of existing tissue such as fat, collagen and others, 5) increased cell permeability that may facilitate the possibility of stimulated gene or medication therapy to tissue, and/or increased permeability of certain tissues to a variety of medications initiated by ultrasound frequencies 10 kHz to 10 MHz, 6) enhanced delivery and/or activation of medicants, 7) stimulation of protein synthesis and/or 8) any other possible tissue response such as coagulative necrosis. Thus, for example, in various embodiments, a low intensity dispersed ultrasound field can be generated to provide for angiogenesis, an increased intensity homogeneous or uniform ultrasound field can be generated to provide for diathermy that increases the rate of healing and rejuvenation, and/or high intensity focused and/or unfocused beams can be generated to provide for temporary ablative and hemostatic effects in a variety of depth and positions of human tissue, whereby a summation or a combined effect of rejuvenation is created by combining ultrasound energy fields.
With reference to
In an embodiment, with reference to
With continued reference to
In an embodiment, suction is used to attach probe 18 to the patient's body. In this embodiment, a negative pressure differential is created, which enables, probe 18 to attach to stratum corneum 85 by suction. A vacuum-type device can be used to create the suction and the vacuum device can be integral with, detachably connected to, or completely separate from probe 18. Using suction to attach probe 18 to stratum corneum 85 I ensures that probe 18 is properly coupled to stratum corneum 85. Further, using suction to attach probe 18 also reduces the thickness of the tissue to make it easier to reach distinct layers of tissue.
Turning now to the embodiments illustrated in
With reference to
A coupling gel may be used to couple probe 18 to ROI 12 at a surface of stratum corneum 85, for example, a surface of a patient's skin. Ultrasound energy may be emitted in various energy fields in this embodiment. With additional reference to
In another embodiment, a transducer 19 may be capable of emitting ultrasound energy for imaging or treatment or combinations thereof. In an embodiment, transducer 19 may be configured to emit ultrasound energy at specific depths in ROI 12 to target a specific tissue. In this embodiment, transducer 19 may be capable of emitting unfocused or defocused ultrasound energy over a wide area in and/or around ROI 12 for treatment purposes.
In various embodiments, a transducer 19 may comprise one or more transduction elements 26 for facilitating treatment. Transducer 19 may further comprise one or more transduction elements 26, such as, for example, elements 26A and 26B as illustrated in
In an embodiment, the thickness of the transduction element 26 of transducer 19 may be configured to be uniform. That is, the transduction element 26 may be configured to have a thickness that is generally substantially the same throughout.
In another embodiment, the transduction element 26 may also be configured with a variable thickness, and/or as a multiple damped device. For example, the transduction element 26 of transducer 19 may be configured to have a first thickness selected to provide a center operating frequency of a lower range, for example from approximately 1 kHz to 3 MHz. The transduction element 26 may also be configured with a second thickness selected to provide a center operating frequency of a higher range, for example from approximately 3 to 100 MHz or more.
In yet another embodiment, transducer 19 may be configured as a single broadband transducer excited with two or more frequencies to provide an adequate output for raising the temperature within ROI 12 to the desired level. Transducer 19 may also be configured as two or more individual transducers, wherein each transducer 19 may comprise a transduction element 26. The thickness of the transduction elements 26 may be configured to provide center-operating frequencies in a desired treatment range. For example, in an embodiment, transducer 19 may comprise a first transducer 19 configured with a first transduction element 26A having a thickness corresponding to a center frequency range of approximately 1 MHz to 3 MHz, and a second transducer 19 configured with a second transduction element 26B having a thickness corresponding to a center frequency of approximately 3 MHz to 100 MHz or more. Various other ranges of thickness for a first and/or second transduction element 26 can also be realized.
Moreover, in an embodiment, any variety of mechanical lenses or variable focus lenses, e.g. liquid-filled lenses, may also be used to focus and or defocus the energy field. For example, with reference to the embodiments depicted in
In various embodiments, transduction elements 26 may be configured to be concave, convex, and/or planar. For example, in the embodiment illustrated in
In another embodiment, as illustrated in
Moreover, transduction element 26 can be any distance from the patient's skin. In that regard, it can be far away from the skin disposed within a long transducer or it can be just a few millimeters from the surface of the patient's skin. In certain embodiments, the transduction element 26 can be positioned closer to the surface of a patient's skin when emitting ultrasound at high frequencies. Moreover, both three and two dimensional arrays of elements can be used in the present invention.
With reference to
With reference to
Transducer 19 may further comprise a reflective surface, tip, or area at the end of the transducer 19 that emits ultrasound energy. This reflective surface may enhance, magnify, or otherwise change ultrasound energy emitted from system 14.
In various embodiments, a probe 18 may be suitably controlled and operated in various manners by control system 20 as illustrated in
For example, in various embodiments of power sourcing components 60, control system 20 may comprise one or more direct current (DC) power supplies 68 capable of providing electrical energy for the entire control system 20, including power required by a transducer electronic amplifier/driver 70. A DC current sense device 72 may also be provided to confirm the level of power entering amplifiers/drivers 70 for safety and monitoring purposes, among others.
In an embodiment, amplifiers/drivers 70 may comprise multi-channel or single channel power amplifiers and/or drivers. In an embodiment for transducer array configurations, amplifiers/drivers 70 may also be configured with a beamformer to facilitate array focusing. In various embodiments, a beamformer may be electrically excited by an oscillator/digitally controlled waveform synthesizer 74 with related switching logic.
Power sourcing components 60 may also comprise various filtering configurations 76. For example, switchable harmonic filters and/or matching may be used at the output of amplifier/driver 70 to increase the drive efficiency and effectiveness. Power detection components 78 may also be included to confirm appropriate operation and calibration. For example, electric power and other energy detection components 78 may be used to monitor the amount of power entering probe 18.
Various sensing and monitoring components 62 may also be suitably implemented within control system 20. For example, in an embodiment, monitoring, sensing, and interface control components 80 may be capable of operating with various motion detection systems implemented within probe 18, to receive and process information such as acoustic or other spatial and temporal information from ROI 12. Sensing and monitoring components 62 may also comprise various controls, interfacing, and switches 82 and/or power detectors 78. Such sensing and monitoring components 62 may facilitate open-loop and/or closed-loop feedback systems within treatment system 14.
In an embodiment, sensing and monitoring components 62 may further comprise a sensor that may be connected to an audio or visual alarm system to prevent overuse of system 14. In this embodiment, the sensor may be capable of sensing the amount of energy transferred to the skin, and/or the time that system 14 has been actively emitting energy. When a certain time or temperature threshold has been reached, the alarm may sound an audible alarm, or cause a visual indicator to activate to alert the user that a threshold has been reached. This may prevent overuse of the system 14. In an embodiment, the sensor may be operatively connected to control system 20 and force control system 20, to stop emitting ultrasound energy from transducer 19.
In an embodiment, a cooling/coupling control system 84 may be provided, and may be capable of removing waste heat from probe 18. Furthermore the cooling/coupling control system 84 may be capable of providing a controlled temperature at the superficial tissue interface and deeper into tissue, and/or provide acoustic coupling from probe 18 to ROI 12. Such cooling/coupling control systems 84 can also be capable of operating in both open-loop and/or closed-loop feedback arrangements with various coupling and feedback components.
Additionally, in various embodiments, an control system 20 may further comprise a system processor and various digital control logic 86, such as one or more of microcontrollers, microprocessors, field-programmable gate arrays, computer boards, and associated components, including firmware and control software 88, which may be capable of interfacing with user controls and interfacing circuits as well as input/output circuits and systems for communications, displays, interfacing, storage, documentation, and other useful functions. System software 88 may be capable of controlling all initialization, timing, level setting, monitoring, safety monitoring, and all other system functions required to accomplish user-defined treatment objectives. Further, various control switches 90 may also be suitably configured to control operation.
With reference to
With reference again to
In various embodiments, for ultrasound energy delivery, transducer 19 may be mechanically and/or electronically scanned to place treatment zones over an extended area in ROI 12. A treatment depth may be adjusted between a range of approximately 1 to 30 millimeters, or any other depth described herein. Such delivery of energy may occur through imaging of the target, within ROI 12 and then applying ultrasound energy at known depths over an extended area without initial or ongoing imaging.
In various embodiments, the ultrasound beam from transducer 19 may be spatially and/or temporally controlled at least in part by changing the spatial parameters of transducer 19, such as the placement, distance, treatment depth and transducer 19 structure, as well as by changing the temporal parameters of transducer 19, such as the frequency, drive amplitude, and timing, with such control handled via control system 20. Such spatial and temporal parameters may also be suitably monitored and/or utilized in open-loop and/or closed-loop feedback systems within ultrasound system 14.
Finally, it should be noted that while this disclosure is directed primarily to using ultrasound energy to conduct procedures non-invasively, that the method and system described above can also utilize energy such as ultrasound energy to assist in invasive procedures. For example, ultrasound energy can be used to ablate tissues during an invasive procedure. In this regard, ultrasound energy can be used for invasive and minimally invasive procedures.
The present invention has been described herein with reference to various embodiments. However, those skilled in the art will recognize that changes and modifications may be made to any of the various embodiments without departing from the scope of the invention. For example, the various operational steps, as well as the components for carrying out the operational steps, may be implemented in alternate ways depending upon the particular application or in consideration of any number of cost functions associated with the operation of the system, for example, various of the steps may be deleted, modified, or combined with other steps.
Further, it should be noted that while the methods and systems for ultrasound treatment, as described herein, are suitable for use by a medical practitioner proximate the patient, the system can also be accessed remotely, for example, the medical practitioner can view through a remote display having imaging information transmitted in various manners of communication, such as by satellite/wireless or by wired connections such as IP or digital cable networks and the like, and can direct a local practitioner as to the suitable placement for the transducer. Moreover, while the various embodiments may comprise non-invasive configurations, systems and methods can also be configured for at least some level of invasive treatment applications.
The various embodiments, as disclosed and illustrated herein, are not to be considered in a limiting sense as numerous variations are possible. The subject matter of the various embodiments of the invention includes any and all novel and non-obvious combinations and sub combinations of the various elements, features, functions and/or properties disclosed herein. These and other changes or modifications are intended to be included within the scope of the present invention, as set forth in the following claims.
This application is a continuation of U.S. patent application Ser. No. 12/954,484 entitled “METHODS AND SYSTEMS FOR GENERATING THERMAL BUBBLES FOR IMPROVED ULTRASOUND IMAGING AND THERAPY” filed on Nov. 24, 2010, issued as U.S. Pat. No. 8,715,186 on May 6, 2014, which claims the benefit of priority from U.S. Provisional No. 61/293,916 filed Nov. 24, 2009, all of which are incorporated in its entirety by reference, herein.
Number | Name | Date | Kind |
---|---|---|---|
2427348 | Bond et al. | Sep 1947 | A |
3913386 | Saglio | Oct 1975 | A |
3965455 | Hurwitz | Jun 1976 | A |
3992925 | Perilhou | Nov 1976 | A |
4039312 | Patru | Aug 1977 | A |
4059098 | Murdock | Nov 1977 | A |
4101795 | Fukumoto | Jul 1978 | A |
4166967 | Benes et al. | Sep 1979 | A |
4211948 | Brisken et al. | Jul 1980 | A |
4211949 | Brisken et al. | Jul 1980 | A |
4213344 | Rose | Jul 1980 | A |
4276491 | Daniel | Jun 1981 | A |
4315514 | Drewes et al. | Feb 1982 | A |
4325381 | Glenn | Apr 1982 | A |
4343301 | Indech | Aug 1982 | A |
4372296 | Fahim | Feb 1983 | A |
4379145 | Masuho et al. | Apr 1983 | A |
4381007 | Doss | Apr 1983 | A |
4381787 | Hottinger | May 1983 | A |
4397314 | Vaguine | Aug 1983 | A |
4409839 | Tanezer | Oct 1983 | A |
4431008 | Wanner et al. | Feb 1984 | A |
4441486 | Pounds | Apr 1984 | A |
4452084 | Taenzer | Jun 1984 | A |
4484569 | Driller et al. | Nov 1984 | A |
4507582 | Glenn | Mar 1985 | A |
4513749 | Kino | Apr 1985 | A |
4513750 | Heyman et al. | Apr 1985 | A |
4527550 | Ruggera et al. | Jul 1985 | A |
4528979 | Marchenko | Jul 1985 | A |
4534221 | Fife et al. | Aug 1985 | A |
4566459 | Umemura et al. | Jan 1986 | A |
4567895 | Putzke | Feb 1986 | A |
4586512 | Do-Huu | May 1986 | A |
4601296 | Yerushalmi | Jul 1986 | A |
4620546 | Aida et al. | Nov 1986 | A |
4637256 | Sugiyama et al. | Jan 1987 | A |
4646756 | Watmough et al. | Mar 1987 | A |
4663358 | Hyon | May 1987 | A |
4668516 | Duraffourd et al. | May 1987 | A |
4672591 | Breimesser et al. | Jun 1987 | A |
4680499 | Umemura et al. | Jul 1987 | A |
4697588 | Reichenberger | Oct 1987 | A |
4754760 | Fukukita et al. | Jul 1988 | A |
4757820 | Itoh | Jul 1988 | A |
4771205 | Mequio | Sep 1988 | A |
4801459 | Liburdy | Jan 1989 | A |
4803625 | Fu et al. | Feb 1989 | A |
4807633 | Fry | Feb 1989 | A |
4817615 | Fukukita et al. | Apr 1989 | A |
4858613 | Fry et al. | Aug 1989 | A |
4860732 | Hasegawa et al. | Aug 1989 | A |
4865041 | Hassler | Sep 1989 | A |
4865042 | Umemura | Sep 1989 | A |
4867169 | Machida | Sep 1989 | A |
4874562 | Hyon | Oct 1989 | A |
4875487 | Seppi | Oct 1989 | A |
4891043 | Zeimer et al. | Jan 1990 | A |
4893624 | Lele | Jan 1990 | A |
4896673 | Rose | Jan 1990 | A |
4900540 | Ryan et al. | Feb 1990 | A |
4901729 | Saitoh et al. | Feb 1990 | A |
4917096 | Englehart | Apr 1990 | A |
4932414 | Coleman et al. | Jun 1990 | A |
4938216 | Lele | Jul 1990 | A |
4938217 | Lele | Jul 1990 | A |
4947046 | Kawabata et al. | Aug 1990 | A |
4951653 | Fry et al. | Aug 1990 | A |
4955365 | Fry et al. | Sep 1990 | A |
4958626 | Nambu | Sep 1990 | A |
4976709 | Sand | Dec 1990 | A |
4979501 | Valchanov | Dec 1990 | A |
4992989 | Watanabe et al. | Feb 1991 | A |
5012797 | Liang | May 1991 | A |
5018508 | Fry et al. | May 1991 | A |
5030874 | Saito et al. | Jul 1991 | A |
5036855 | Fry et al. | Aug 1991 | A |
5040537 | Katakura | Aug 1991 | A |
5054310 | Flynn | Oct 1991 | A |
5054470 | Fry et al. | Oct 1991 | A |
5070879 | Herres | Dec 1991 | A |
5088495 | Miyagawa | Feb 1992 | A |
5115814 | Griffith | May 1992 | A |
5117832 | Sanghvi et al. | Jun 1992 | A |
5123418 | Saurel | Jun 1992 | A |
5143063 | Fellner | Sep 1992 | A |
5143074 | Dory | Sep 1992 | A |
5149319 | Unger | Sep 1992 | A |
5150711 | Dory | Sep 1992 | A |
5150714 | Green | Sep 1992 | A |
5152294 | Mochizuki et al. | Oct 1992 | A |
5156144 | Iwasaki | Oct 1992 | A |
5158536 | Sekins | Oct 1992 | A |
5159931 | Pini | Nov 1992 | A |
5163421 | Bernstein | Nov 1992 | A |
5163436 | Saitoh et al. | Nov 1992 | A |
5178135 | Uchiyama et al. | Jan 1993 | A |
5190518 | Takasu | Mar 1993 | A |
5190766 | Ishihara | Mar 1993 | A |
5191880 | McLeod | Mar 1993 | A |
5205287 | Erbel et al. | Apr 1993 | A |
5209720 | Unger | May 1993 | A |
5212671 | Fujii et al. | May 1993 | A |
5215680 | D Arrigo | Jun 1993 | A |
5224467 | Oku | Jul 1993 | A |
5230334 | Klopotek | Jul 1993 | A |
5230338 | Allen et al. | Jul 1993 | A |
5247924 | Suzuki et al. | Sep 1993 | A |
5255681 | Ishimura et al. | Oct 1993 | A |
5257970 | Dougherty | Nov 1993 | A |
5265614 | Hayakawa | Nov 1993 | A |
5267985 | Shimada et al. | Dec 1993 | A |
5269297 | Weng | Dec 1993 | A |
5282797 | Chess | Feb 1994 | A |
5295484 | Marcus et al. | Mar 1994 | A |
5295486 | Wollschlaeger et al. | Mar 1994 | A |
5304169 | Sand | Apr 1994 | A |
5305756 | Entrekin et al. | Apr 1994 | A |
5321520 | Inga et al. | Jun 1994 | A |
5323779 | Hardy et al. | Jun 1994 | A |
5327895 | Hashimoto et al. | Jul 1994 | A |
5348016 | Unger et al. | Sep 1994 | A |
5360268 | Hayashi | Nov 1994 | A |
5370121 | Reichenberger et al. | Dec 1994 | A |
5371483 | Bhardwaj | Dec 1994 | A |
5375602 | Lancee et al. | Dec 1994 | A |
5379773 | Hornsby | Jan 1995 | A |
5380280 | Peterson | Jan 1995 | A |
5380519 | Schneider et al. | Jan 1995 | A |
5383917 | Desai et al. | Jan 1995 | A |
5391140 | Schaetzle et al. | Feb 1995 | A |
5391197 | Burdette et al. | Feb 1995 | A |
5392259 | Bolorforosh | Feb 1995 | A |
5396143 | Seyed-Bolorforosh et al. | Mar 1995 | A |
5398689 | Connor et al. | Mar 1995 | A |
5406503 | Williams, Jr. et al. | Apr 1995 | A |
5417216 | Tanaka | May 1995 | A |
5419327 | Rohwedder | May 1995 | A |
5423220 | Finsterwald et al. | Jun 1995 | A |
5435311 | Umemura et al. | Jul 1995 | A |
5438998 | Hanafy | Aug 1995 | A |
5458596 | Lax | Oct 1995 | A |
5460179 | Okunuki et al. | Oct 1995 | A |
5460595 | Hall et al. | Oct 1995 | A |
5469854 | Unger et al. | Nov 1995 | A |
5471988 | Fujio | Dec 1995 | A |
5487388 | Rello et al. | Jan 1996 | A |
5492126 | Hennige et al. | Feb 1996 | A |
5496256 | Bock | Mar 1996 | A |
5501655 | Rolt et al. | Mar 1996 | A |
5503152 | Oakley et al. | Apr 1996 | A |
5503320 | Webster et al. | Apr 1996 | A |
5507790 | Weiss | Apr 1996 | A |
5520188 | Hennige et al. | May 1996 | A |
5522869 | Burdette et al. | Jun 1996 | A |
5523058 | Umemura et al. | Jun 1996 | A |
5524620 | Rosenschein | Jun 1996 | A |
5524624 | Tepper | Jun 1996 | A |
5524625 | Okazaki et al. | Jun 1996 | A |
5526624 | Berg | Jun 1996 | A |
5526812 | Dumoulin et al. | Jun 1996 | A |
5526814 | Cline et al. | Jun 1996 | A |
5526815 | Granz et al. | Jun 1996 | A |
5529070 | Augustine et al. | Jun 1996 | A |
5540235 | Wilson | Jul 1996 | A |
5558092 | Unger et al. | Sep 1996 | A |
5560362 | Sliwa et al. | Oct 1996 | A |
5575291 | Hayakawa | Nov 1996 | A |
5575807 | Faller | Nov 1996 | A |
5577502 | Darrow et al. | Nov 1996 | A |
5577507 | Snyder et al. | Nov 1996 | A |
5577991 | Akui et al. | Nov 1996 | A |
5580575 | Unger et al. | Dec 1996 | A |
5601526 | Chapelon et al. | Feb 1997 | A |
5603323 | Pflugrath et al. | Feb 1997 | A |
5609562 | Kaali | Mar 1997 | A |
5615091 | Palatnik | Mar 1997 | A |
5617858 | Taverna et al. | Apr 1997 | A |
5618275 | Bock | Apr 1997 | A |
5620479 | Diederich | Apr 1997 | A |
5622175 | Sudol et al. | Apr 1997 | A |
5638819 | Manwaring et al. | Jun 1997 | A |
5643179 | Fujimoto | Jul 1997 | A |
5644085 | Lorraine et al. | Jul 1997 | A |
5647373 | Paltieli | Jul 1997 | A |
5655535 | Friemel et al. | Aug 1997 | A |
5655538 | Lorraine | Aug 1997 | A |
5657760 | Ying et al. | Aug 1997 | A |
5658328 | Johnson | Aug 1997 | A |
5660836 | Knowlton | Aug 1997 | A |
5662116 | Kondo et al. | Sep 1997 | A |
5665053 | Jacobs | Sep 1997 | A |
5665141 | Vago | Sep 1997 | A |
5671746 | Dreschel et al. | Sep 1997 | A |
5673699 | Trahey et al. | Oct 1997 | A |
5676692 | Sanghvi et al. | Oct 1997 | A |
5685820 | Riek et al. | Nov 1997 | A |
5687737 | Branham et al. | Nov 1997 | A |
5690608 | Watanabe | Nov 1997 | A |
5694936 | Fujimoto et al. | Dec 1997 | A |
5697897 | Buchholtz et al. | Dec 1997 | A |
5701900 | Shehada et al. | Dec 1997 | A |
5704361 | Seward et al. | Jan 1998 | A |
5706252 | Le Verrier et al. | Jan 1998 | A |
5706564 | Rhyne | Jan 1998 | A |
5715823 | Wood et al. | Feb 1998 | A |
5720287 | Chapelon et al. | Feb 1998 | A |
5722411 | Suzuki et al. | Mar 1998 | A |
5727554 | Kalend et al. | Mar 1998 | A |
5735280 | Sherman et al. | Apr 1998 | A |
5743863 | Chapelon | Apr 1998 | A |
5746005 | Steinberg | May 1998 | A |
5746762 | Bass | May 1998 | A |
5748767 | Raab | May 1998 | A |
5749364 | Sliwa et al. | May 1998 | A |
5755228 | Wilson et al. | May 1998 | A |
5755753 | Knowlton | May 1998 | A |
5762066 | Law et al. | Jun 1998 | A |
5763886 | Schulte | Jun 1998 | A |
5769790 | Watkins et al. | Jun 1998 | A |
5779644 | Eberle et al. | Jul 1998 | A |
5792058 | Lee et al. | Aug 1998 | A |
5795297 | Daigle | Aug 1998 | A |
5795311 | Wess | Aug 1998 | A |
5810009 | Mine et al. | Sep 1998 | A |
5810888 | Fenn | Sep 1998 | A |
5814599 | Mitragotri et al. | Sep 1998 | A |
5817013 | Ginn et al. | Oct 1998 | A |
5817021 | Reichenberger | Oct 1998 | A |
5820564 | Slayton | Oct 1998 | A |
5823962 | Schaetzle et al. | Oct 1998 | A |
5827204 | Grandia et al. | Oct 1998 | A |
5839751 | Bonin | Nov 1998 | A |
5840032 | Hatfield et al. | Nov 1998 | A |
5844140 | Seale | Dec 1998 | A |
5853367 | Chalek et al. | Dec 1998 | A |
5869751 | Bonin | Feb 1999 | A |
5871524 | Knowlton | Feb 1999 | A |
5873902 | Sanghvi et al. | Feb 1999 | A |
5876431 | Spehr et al. | Mar 1999 | A |
5879303 | Averkiou et al. | Mar 1999 | A |
5882557 | Hayakawa | Mar 1999 | A |
5891034 | Bucholz | Apr 1999 | A |
5899861 | Friemel et al. | May 1999 | A |
5904659 | Duarte | May 1999 | A |
5919219 | Knowlton | Jul 1999 | A |
5923099 | Bilir | Jul 1999 | A |
5924989 | Polz | Jul 1999 | A |
5928169 | Schaetzle et al. | Jul 1999 | A |
5931805 | Brisken | Aug 1999 | A |
5938606 | Bonnefous | Aug 1999 | A |
5938612 | Kline-Schoder | Aug 1999 | A |
5948011 | Knowlton | Sep 1999 | A |
5957844 | Dekel | Sep 1999 | A |
5957882 | Nita et al. | Sep 1999 | A |
5957941 | Ream | Sep 1999 | A |
5967980 | Ferre et al. | Oct 1999 | A |
5968034 | Fulmer | Oct 1999 | A |
5971949 | Levin | Oct 1999 | A |
5977538 | Unger et al. | Nov 1999 | A |
5984882 | Rosenschein et al. | Nov 1999 | A |
5990598 | Sudol et al. | Nov 1999 | A |
5997471 | Gumb et al. | Dec 1999 | A |
5997497 | Nita et al. | Dec 1999 | A |
5999843 | Anbar | Dec 1999 | A |
6004262 | Putz et al. | Dec 1999 | A |
6007499 | Martin et al. | Dec 1999 | A |
6013032 | Savord | Jan 2000 | A |
6016255 | Bolan et al. | Jan 2000 | A |
6019724 | Gronningsaeter et al. | Feb 2000 | A |
6022308 | Williams | Feb 2000 | A |
6022327 | Chang | Feb 2000 | A |
6036646 | Barthe | Mar 2000 | A |
6039048 | Silberg | Mar 2000 | A |
6039689 | Lizzi | Mar 2000 | A |
6042556 | Beach et al. | Mar 2000 | A |
6049159 | Barthe | Apr 2000 | A |
6050943 | Slayton et al. | Apr 2000 | A |
6059727 | Fowlkes | May 2000 | A |
6071239 | Cribbs et al. | Jun 2000 | A |
6080108 | Dunham | Jun 2000 | A |
6083148 | Williams | Jul 2000 | A |
6086535 | Ishibashi et al. | Jul 2000 | A |
6086580 | Mordon et al. | Jul 2000 | A |
6090054 | Tagishi | Jul 2000 | A |
6093883 | Sanghvi | Jul 2000 | A |
6101407 | Groezinger | Aug 2000 | A |
6106469 | Suzuki et al. | Aug 2000 | A |
6113558 | Rosenschein et al. | Sep 2000 | A |
6113559 | Klopotek | Sep 2000 | A |
6120452 | Barthe | Sep 2000 | A |
6123081 | Durette | Sep 2000 | A |
6126619 | Peterson et al. | Oct 2000 | A |
6135971 | Hutchinson et al. | Oct 2000 | A |
6139499 | Wilk | Oct 2000 | A |
6159150 | Yale et al. | Dec 2000 | A |
6171244 | Finger et al. | Jan 2001 | B1 |
6176840 | Nishimura | Jan 2001 | B1 |
6183426 | Akisada | Feb 2001 | B1 |
6183502 | Takeuchi | Feb 2001 | B1 |
6183773 | Anderson | Feb 2001 | B1 |
6190323 | Digs | Feb 2001 | B1 |
6190336 | Duarte | Feb 2001 | B1 |
6193658 | Wendelken et al. | Feb 2001 | B1 |
6210327 | Brackett et al. | Apr 2001 | B1 |
6213948 | Barthe | Apr 2001 | B1 |
6216029 | Paltieli | Apr 2001 | B1 |
6233476 | Strommer et al. | May 2001 | B1 |
6234990 | Rowe et al. | May 2001 | B1 |
6241753 | Knowlton | Jun 2001 | B1 |
6246898 | Vesely et al. | Jun 2001 | B1 |
6251074 | Averkiou et al. | Jun 2001 | B1 |
6251088 | Kaufman et al. | Jun 2001 | B1 |
6268405 | Yao | Jul 2001 | B1 |
6273864 | Duarte | Aug 2001 | B1 |
6280402 | Ishibashi et al. | Aug 2001 | B1 |
6287257 | Matichuk | Sep 2001 | B1 |
6296619 | Brisken | Oct 2001 | B1 |
6301989 | Brown et al. | Oct 2001 | B1 |
6309355 | Cain et al. | Oct 2001 | B1 |
6311090 | Knowlton | Oct 2001 | B1 |
6315741 | Martin | Nov 2001 | B1 |
6322509 | Pan et al. | Nov 2001 | B1 |
6322532 | D'Sa | Nov 2001 | B1 |
6325540 | Lounsberry et al. | Dec 2001 | B1 |
6325758 | Carol et al. | Dec 2001 | B1 |
6325769 | Klopotek | Dec 2001 | B1 |
6325798 | Edwards et al. | Dec 2001 | B1 |
6338716 | Hossack et al. | Jan 2002 | B1 |
6350276 | Knowlton | Feb 2002 | B1 |
6356780 | Licato et al. | Mar 2002 | B1 |
6361531 | Hissong | Mar 2002 | B1 |
6370411 | Osadchy et al. | Apr 2002 | B1 |
6375672 | Aksan | Apr 2002 | B1 |
6377854 | Knowlton | Apr 2002 | B1 |
6377855 | Knowlton | Apr 2002 | B1 |
6381497 | Knowlton | Apr 2002 | B1 |
6381498 | Knowlton | Apr 2002 | B1 |
6387380 | Knowlton | May 2002 | B1 |
6390982 | Bova et al. | May 2002 | B1 |
6405090 | Knowlton | Jun 2002 | B1 |
6409720 | Hissong | Jun 2002 | B1 |
6413216 | Cain et al. | Jul 2002 | B1 |
6413253 | Koop | Jul 2002 | B1 |
6413254 | Hissong | Jul 2002 | B1 |
6419648 | Vitek | Jul 2002 | B1 |
6423007 | Lizzi et al. | Jul 2002 | B2 |
6425865 | Salcudean | Jul 2002 | B1 |
6425867 | Vaezy et al. | Jul 2002 | B1 |
6425912 | Knowlton | Jul 2002 | B1 |
6428477 | Mason | Aug 2002 | B1 |
6428532 | Doukas | Aug 2002 | B1 |
6430446 | Knowlton | Aug 2002 | B1 |
6432057 | Mazess et al. | Aug 2002 | B1 |
6432067 | Martin et al. | Aug 2002 | B1 |
6432101 | Weber | Aug 2002 | B1 |
6436061 | Costantino | Aug 2002 | B1 |
6438424 | Knowlton | Aug 2002 | B1 |
6440071 | Slayton | Aug 2002 | B1 |
6440121 | Weber | Aug 2002 | B1 |
6443914 | Costantino | Sep 2002 | B1 |
6453202 | Knowlton | Sep 2002 | B1 |
6461378 | Knowlton | Oct 2002 | B1 |
6470216 | Knowlton | Oct 2002 | B1 |
6488626 | Lizzi et al. | Dec 2002 | B1 |
6491657 | Rowe | Dec 2002 | B2 |
6500121 | Slayton | Dec 2002 | B1 |
6500141 | Irion | Dec 2002 | B1 |
6508774 | Acker et al. | Jan 2003 | B1 |
6511427 | Sliwa, Jr. et al. | Jan 2003 | B1 |
6511428 | Azuma | Jan 2003 | B1 |
6514244 | Pope | Feb 2003 | B2 |
6517484 | Wilk et al. | Feb 2003 | B1 |
6524250 | Weber | Feb 2003 | B1 |
6540679 | Slayton | Apr 2003 | B2 |
6540685 | Rhoads et al. | Apr 2003 | B1 |
6540700 | Fujimoto et al. | Apr 2003 | B1 |
6554771 | Buil et al. | Apr 2003 | B1 |
6569099 | Babaev | May 2003 | B1 |
6569108 | Sarvazyan et al. | May 2003 | B2 |
6572552 | Fukukita | Jun 2003 | B2 |
6575956 | Brisken et al. | Jun 2003 | B1 |
6595934 | Hissong | Jul 2003 | B1 |
6599256 | Acker | Jul 2003 | B1 |
6607498 | Eshel | Aug 2003 | B2 |
6618620 | Freundlich et al. | Sep 2003 | B1 |
6623430 | Slayton | Sep 2003 | B1 |
6626854 | Friedman | Sep 2003 | B2 |
6626855 | Weng et al. | Sep 2003 | B1 |
6638226 | He et al. | Oct 2003 | B2 |
6645162 | Friedman | Nov 2003 | B2 |
6662054 | Kreindel | Dec 2003 | B2 |
6663627 | Francischelli | Dec 2003 | B2 |
6665806 | Shimizu | Dec 2003 | B1 |
6666835 | Martin | Dec 2003 | B2 |
6669638 | Miller et al. | Dec 2003 | B1 |
6685640 | Fry | Feb 2004 | B1 |
6692450 | Coleman | Feb 2004 | B1 |
6699237 | Weber | Mar 2004 | B2 |
6716184 | Vaezy et al. | Apr 2004 | B2 |
6719449 | Lauglin | Apr 2004 | B1 |
6719694 | Weng et al. | Apr 2004 | B2 |
6726627 | Lizzi et al. | Apr 2004 | B1 |
6825176 | Mourad | Apr 2004 | B2 |
6733449 | Krishnamurthy et al. | May 2004 | B1 |
6749624 | Knowlton | Jun 2004 | B2 |
6773409 | Truckai et al. | Aug 2004 | B2 |
6775404 | Pagoulatos et al. | Aug 2004 | B1 |
6790187 | Thompson et al. | Sep 2004 | B2 |
6824516 | Batten et al. | Nov 2004 | B2 |
6835940 | Morikawa et al. | Dec 2004 | B2 |
6846290 | Lizzi et al. | Jan 2005 | B2 |
6875176 | Mourad et al. | Apr 2005 | B2 |
6882884 | Mosk et al. | Apr 2005 | B1 |
6887239 | Elstrom et al. | May 2005 | B2 |
6889089 | Behl | May 2005 | B2 |
6896657 | Willis | May 2005 | B2 |
6902536 | Manna et al. | Jun 2005 | B2 |
6905466 | Salgo | Jun 2005 | B2 |
6918907 | Kelly | Jul 2005 | B2 |
6920883 | Bessette | Jul 2005 | B2 |
6921371 | Wilson | Jul 2005 | B2 |
6932771 | Whitmore | Aug 2005 | B2 |
6932814 | Wood | Aug 2005 | B2 |
6936044 | McDaniel | Aug 2005 | B2 |
6936046 | Hissong | Aug 2005 | B2 |
6945937 | Culp et al. | Sep 2005 | B2 |
6948843 | Laugharn et al. | Sep 2005 | B2 |
6953941 | Nakano et al. | Oct 2005 | B2 |
6958043 | Hissong | Oct 2005 | B2 |
6971994 | Young et al. | Dec 2005 | B1 |
6974417 | Lockwood et al. | Dec 2005 | B2 |
6976492 | Ingle | Dec 2005 | B2 |
6992305 | Maezawa et al. | Jan 2006 | B2 |
6997923 | Anderson | Feb 2006 | B2 |
7006874 | Knowlton | Feb 2006 | B2 |
7020528 | Neev | Mar 2006 | B2 |
7022089 | Ooba | Apr 2006 | B2 |
7058440 | Heuscher et al. | Jun 2006 | B2 |
7063666 | Weng et al. | Jun 2006 | B2 |
7070565 | Vaezy et al. | Jul 2006 | B2 |
7074218 | Washington et al. | Jul 2006 | B2 |
7094252 | Koop | Aug 2006 | B2 |
7108663 | Talish et al. | Sep 2006 | B2 |
7115123 | Knowlton | Oct 2006 | B2 |
7122029 | Koop et al. | Oct 2006 | B2 |
7142905 | Slayton | Nov 2006 | B2 |
7165451 | Brooks et al. | Jan 2007 | B1 |
7179238 | Hissong | Feb 2007 | B2 |
7189230 | Knowlton | Mar 2007 | B2 |
7229411 | Slayton | Jun 2007 | B2 |
7235592 | Muratoglu | Jun 2007 | B2 |
7258674 | Cribbs | Aug 2007 | B2 |
7273459 | Desilets | Sep 2007 | B2 |
7294125 | Phalen et al. | Nov 2007 | B2 |
7297117 | Trucco et al. | Nov 2007 | B2 |
7303555 | Makin et al. | Dec 2007 | B2 |
7327071 | Nishiyama et al. | Feb 2008 | B2 |
7331951 | Eshel et al. | Feb 2008 | B2 |
7332985 | Larson, III et al. | Feb 2008 | B2 |
7347855 | Eshel | Mar 2008 | B2 |
RE40403 | Cho et al. | Jun 2008 | E |
7393325 | Barthe | Jul 2008 | B2 |
7398116 | Edwards | Jul 2008 | B2 |
7399279 | Abend et al. | Jul 2008 | B2 |
7491171 | Barthe et al. | Feb 2009 | B2 |
7510536 | Foley et al. | Mar 2009 | B2 |
7530356 | Slayton | May 2009 | B2 |
7530958 | Slayton | May 2009 | B2 |
7571336 | Barthe | Aug 2009 | B2 |
7601120 | Moilanen et al. | Oct 2009 | B2 |
7615015 | Coleman | Nov 2009 | B2 |
7615016 | Barthe | Nov 2009 | B2 |
7686763 | Vaezy et al. | Mar 2010 | B2 |
7695437 | Quistgaard et al. | Apr 2010 | B2 |
7758524 | Barthe | Jul 2010 | B2 |
7789841 | Huckle et al. | Sep 2010 | B2 |
7824348 | Barthe et al. | Nov 2010 | B2 |
7846096 | Mast et al. | Dec 2010 | B2 |
7857773 | Desilets et al. | Dec 2010 | B2 |
7875023 | Eshel et al. | Jan 2011 | B2 |
7914453 | Slayton et al. | Mar 2011 | B2 |
7914469 | Torbati | Mar 2011 | B2 |
7931611 | Novak et al. | Apr 2011 | B2 |
7955281 | Pedersen et al. | Jun 2011 | B2 |
7967764 | Lidgren et al. | Jun 2011 | B2 |
7967839 | Flock et al. | Jun 2011 | B2 |
8057389 | Barthe et al. | Nov 2011 | B2 |
8057465 | Sliwa, Jr. et al. | Nov 2011 | B2 |
8066641 | Barthe et al. | Nov 2011 | B2 |
8123707 | Huckle et al. | Feb 2012 | B2 |
8128618 | Gliklich et al. | Mar 2012 | B2 |
8133180 | Slayton et al. | Mar 2012 | B2 |
8133191 | Rosenberg et al. | Mar 2012 | B2 |
8166332 | Barthe et al. | Apr 2012 | B2 |
8197409 | Foley et al. | Jun 2012 | B2 |
8206299 | Foley et al. | Jun 2012 | B2 |
8211017 | Foley et al. | Jul 2012 | B2 |
8262591 | Pedersen et al. | Sep 2012 | B2 |
8273037 | Kreindel et al. | Sep 2012 | B2 |
8282554 | Makin et al. | Oct 2012 | B2 |
8333700 | Barthe et al. | Dec 2012 | B1 |
8366622 | Slayton et al. | Feb 2013 | B2 |
8409097 | Slayton et al. | Apr 2013 | B2 |
8444562 | Barthe et al. | May 2013 | B2 |
8480585 | Slayton et al. | Jul 2013 | B2 |
8506486 | Slayton et al. | Aug 2013 | B2 |
8523775 | Barthe et al. | Sep 2013 | B2 |
8535228 | Slayton et al. | Sep 2013 | B2 |
8585618 | Hunziker et al. | Nov 2013 | B2 |
8636665 | Slayton et al. | Jan 2014 | B2 |
8641622 | Barthe et al. | Feb 2014 | B2 |
8663112 | Slayton et al. | Mar 2014 | B2 |
8672848 | Slayton et al. | Mar 2014 | B2 |
8690778 | Slayton et al. | Apr 2014 | B2 |
8690779 | Slayton et al. | Apr 2014 | B2 |
8690780 | Slayton et al. | Apr 2014 | B2 |
8708935 | Barthe et al. | Apr 2014 | B2 |
8715186 | Slayton et al. | May 2014 | B2 |
8726781 | Eckhoff et al. | May 2014 | B2 |
20010009997 | Pope | Jul 2001 | A1 |
20010009999 | Kaufman et al. | Jul 2001 | A1 |
20010014780 | Martin et al. | Aug 2001 | A1 |
20010014819 | Ingle et al. | Aug 2001 | A1 |
20010031922 | Weng et al. | Oct 2001 | A1 |
20010039380 | Larson et al. | Nov 2001 | A1 |
20010041880 | Brisken | Nov 2001 | A1 |
20020000763 | Jones | Jan 2002 | A1 |
20020002345 | Marlinghaus | Jan 2002 | A1 |
20020040199 | Klopotek | Apr 2002 | A1 |
20020040442 | Ishidera | Apr 2002 | A1 |
20020052550 | Madsen et al. | May 2002 | A1 |
20020055702 | Atala | May 2002 | A1 |
20020062077 | Emmenegger et al. | May 2002 | A1 |
20020062142 | Knowlton | May 2002 | A1 |
20020072691 | Thompson et al. | Jun 2002 | A1 |
20020082528 | Friedman et al. | Jun 2002 | A1 |
20020082529 | Suorsa et al. | Jun 2002 | A1 |
20020082589 | Friedman et al. | Jun 2002 | A1 |
20020087080 | Slayton et al. | Jul 2002 | A1 |
20020095143 | Key | Jul 2002 | A1 |
20020099094 | Anderson | Jul 2002 | A1 |
20020115917 | Honda et al. | Aug 2002 | A1 |
20020128648 | Weber | Sep 2002 | A1 |
20020143252 | Dunne et al. | Oct 2002 | A1 |
20020156400 | Babaev | Oct 2002 | A1 |
20020161357 | Anderson | Oct 2002 | A1 |
20020165529 | Danek | Nov 2002 | A1 |
20020168049 | Schriever | Nov 2002 | A1 |
20020169394 | Eppstein et al. | Nov 2002 | A1 |
20020169442 | Neev | Nov 2002 | A1 |
20020173721 | Grunwald et al. | Nov 2002 | A1 |
20020193784 | Mchale et al. | Dec 2002 | A1 |
20020193831 | Smith | Dec 2002 | A1 |
20030009153 | Brisken et al. | Jan 2003 | A1 |
20030014039 | Barzell et al. | Jan 2003 | A1 |
20030018255 | Martin | Jan 2003 | A1 |
20030028111 | Vaezy et al. | Feb 2003 | A1 |
20030028113 | Gilbert et al. | Feb 2003 | A1 |
20030032900 | Ella | Feb 2003 | A1 |
20030036706 | Slayton et al. | Feb 2003 | A1 |
20030040739 | Koop | Feb 2003 | A1 |
20030050678 | Sierra | Mar 2003 | A1 |
20030055417 | Truckai et al. | Mar 2003 | A1 |
20030060736 | Martin et al. | Mar 2003 | A1 |
20030065313 | Koop | Apr 2003 | A1 |
20030074023 | Kaplan | Apr 2003 | A1 |
20030083536 | Eshel | May 2003 | A1 |
20030092988 | Makin | May 2003 | A1 |
20030097071 | Halmann et al. | May 2003 | A1 |
20030099383 | Lefevbre | May 2003 | A1 |
20030125629 | Ustuner | Jul 2003 | A1 |
20030139790 | Ingle et al. | Jul 2003 | A1 |
20030171678 | Batten et al. | Sep 2003 | A1 |
20030171701 | Babaev | Sep 2003 | A1 |
20030176790 | Slayton | Sep 2003 | A1 |
20030191396 | Sanghvi | Oct 2003 | A1 |
20030200481 | Stanley | Oct 2003 | A1 |
20030212129 | Liu et al. | Nov 2003 | A1 |
20030212351 | Hissong | Nov 2003 | A1 |
20030212393 | Knowlton | Nov 2003 | A1 |
20030216795 | Harth | Nov 2003 | A1 |
20030220536 | Hissong | Nov 2003 | A1 |
20030220585 | Hissong | Nov 2003 | A1 |
20030229331 | Brisken et al. | Dec 2003 | A1 |
20030233085 | Giammarusti | Dec 2003 | A1 |
20030236487 | Knowlton | Dec 2003 | A1 |
20040000316 | Knowlton | Jan 2004 | A1 |
20040001809 | Brisken | Jan 2004 | A1 |
20040002705 | Knowlton | Jan 2004 | A1 |
20040010222 | Nunomura et al. | Jan 2004 | A1 |
20040015106 | Coleman | Jan 2004 | A1 |
20040030227 | Littrup | Feb 2004 | A1 |
20040039312 | Hillstead | Feb 2004 | A1 |
20040039418 | Elstrom et al. | Feb 2004 | A1 |
20040041563 | Lewin et al. | Mar 2004 | A1 |
20040041880 | Ikeda et al. | Mar 2004 | A1 |
20040042168 | Yang et al. | Mar 2004 | A1 |
20040044375 | Diederich et al. | Mar 2004 | A1 |
20040049134 | Tosaya et al. | Mar 2004 | A1 |
20040049734 | Simske | Mar 2004 | A1 |
20040059266 | Fry | Mar 2004 | A1 |
20040068186 | Ishida et al. | Apr 2004 | A1 |
20040073079 | Altshuler et al. | Apr 2004 | A1 |
20040073113 | Salgo | Apr 2004 | A1 |
20040073115 | Horzewski et al. | Apr 2004 | A1 |
20040073116 | Smith | Apr 2004 | A1 |
20040073204 | Ryan et al. | Apr 2004 | A1 |
20040077977 | Ella et al. | Apr 2004 | A1 |
20040082857 | Schonenberger et al. | Apr 2004 | A1 |
20040082859 | Schaer | Apr 2004 | A1 |
20040102697 | Evron | May 2004 | A1 |
20040105559 | Aylward et al. | Jun 2004 | A1 |
20040122323 | Vortman et al. | Jun 2004 | A1 |
20040122493 | Ishbashi et al. | Jun 2004 | A1 |
20040143297 | Ramsey | Jul 2004 | A1 |
20040152982 | Hwang et al. | Aug 2004 | A1 |
20040158150 | Rabiner et al. | Aug 2004 | A1 |
20040186535 | Knowlton | Sep 2004 | A1 |
20040189155 | Funakubo | Sep 2004 | A1 |
20040206365 | Knowlton | Oct 2004 | A1 |
20040210214 | Knowlton | Oct 2004 | A1 |
20040217675 | Desilets | Nov 2004 | A1 |
20040249318 | Tanaka | Dec 2004 | A1 |
20040254620 | Lacoste et al. | Dec 2004 | A1 |
20040267252 | Washington et al. | Dec 2004 | A1 |
20050033201 | Takahashi | Feb 2005 | A1 |
20050033316 | Kertz | Feb 2005 | A1 |
20050038340 | Vaezy et al. | Feb 2005 | A1 |
20050055073 | Weber | Mar 2005 | A1 |
20050061834 | Garcia et al. | Mar 2005 | A1 |
20050070961 | Maki et al. | Mar 2005 | A1 |
20050074407 | Smith | Apr 2005 | A1 |
20050080469 | Larson | Apr 2005 | A1 |
20050091770 | Mourad et al. | May 2005 | A1 |
20050096542 | Weng et al. | May 2005 | A1 |
20050104690 | Larson, III et al. | May 2005 | A1 |
20050113689 | Gritzky | May 2005 | A1 |
20050134314 | Prather et al. | Jun 2005 | A1 |
20050137656 | Malak | Jun 2005 | A1 |
20050143677 | Young et al. | Jun 2005 | A1 |
20050154313 | Desilets | Jul 2005 | A1 |
20050154314 | Quistgaard | Jul 2005 | A1 |
20050154332 | Zanelli | Jul 2005 | A1 |
20050154431 | Quistgaard | Jul 2005 | A1 |
20050187495 | Quistgaard | Aug 2005 | A1 |
20050191252 | Mitsui | Sep 2005 | A1 |
20050193451 | Quistgaard et al. | Sep 2005 | A1 |
20050197681 | Barolet et al. | Sep 2005 | A1 |
20050228281 | Nefos | Oct 2005 | A1 |
20050240170 | Zhang et al. | Oct 2005 | A1 |
20050251120 | Anderson et al. | Nov 2005 | A1 |
20050256406 | Barthe | Nov 2005 | A1 |
20050261584 | Eshel | Nov 2005 | A1 |
20050261585 | Makin et al. | Nov 2005 | A1 |
20050267454 | Hissong | Dec 2005 | A1 |
20050288748 | Li et al. | Dec 2005 | A1 |
20060004306 | Altshuler | Jan 2006 | A1 |
20060020260 | Dover et al. | Jan 2006 | A1 |
20060025756 | Francischelli | Feb 2006 | A1 |
20060042201 | Curry | Mar 2006 | A1 |
20060058664 | Barthe | Mar 2006 | A1 |
20060058671 | Vitek et al. | Mar 2006 | A1 |
20060058707 | Barthe | Mar 2006 | A1 |
20060058712 | Altshuler et al. | Mar 2006 | A1 |
20060074309 | Bonnefous | Apr 2006 | A1 |
20060074313 | Slayton et al. | Apr 2006 | A1 |
20060074314 | Slayton | Apr 2006 | A1 |
20060074355 | Slayton | Apr 2006 | A1 |
20060079816 | Barthe | Apr 2006 | A1 |
20060079868 | Makin | Apr 2006 | A1 |
20060084891 | Barthe | Apr 2006 | A1 |
20060089632 | Barthe | Apr 2006 | A1 |
20060089688 | Panescu | Apr 2006 | A1 |
20060094988 | Tosaya et al. | May 2006 | A1 |
20060111744 | Makin | May 2006 | A1 |
20060116583 | Ogasawara et al. | Jun 2006 | A1 |
20060116671 | Slayton | Jun 2006 | A1 |
20060122508 | Slayton | Jun 2006 | A1 |
20060122509 | Desilets | Jun 2006 | A1 |
20060161062 | Arditi et al. | Jul 2006 | A1 |
20060184069 | Vaitekunas | Aug 2006 | A1 |
20060184071 | Klopotek | Aug 2006 | A1 |
20060189972 | Grossman | Aug 2006 | A1 |
20060206105 | Chopra | Sep 2006 | A1 |
20060229514 | Wiener | Oct 2006 | A1 |
20060241440 | Eshel | Oct 2006 | A1 |
20060241442 | Barthe | Oct 2006 | A1 |
20060241470 | Novak et al. | Oct 2006 | A1 |
20060250046 | Koizumi et al. | Nov 2006 | A1 |
20060261584 | Eshel | Nov 2006 | A1 |
20060282691 | Barthe | Dec 2006 | A1 |
20060291710 | Wang et al. | Dec 2006 | A1 |
20070032784 | Gliklich et al. | Feb 2007 | A1 |
20070035201 | Desilets | Feb 2007 | A1 |
20070055154 | Torbati | Mar 2007 | A1 |
20070055155 | Owen et al. | Mar 2007 | A1 |
20070055156 | Desilets | Mar 2007 | A1 |
20070065420 | Johnson | Mar 2007 | A1 |
20070083120 | Cain et al. | Apr 2007 | A1 |
20070087060 | Dietrich | Apr 2007 | A1 |
20070088245 | Babaev et al. | Apr 2007 | A1 |
20070088346 | Mirizzi et al. | Apr 2007 | A1 |
20070161902 | Dan | Jul 2007 | A1 |
20070166357 | Shaffer et al. | Jul 2007 | A1 |
20070167709 | Slayton | Jul 2007 | A1 |
20070208253 | Slayton | Sep 2007 | A1 |
20070219604 | Yaroslavsky et al. | Sep 2007 | A1 |
20070219605 | Yaroslavsky et al. | Sep 2007 | A1 |
20070238994 | Stecco et al. | Oct 2007 | A1 |
20070239075 | Rosenberg et al. | Oct 2007 | A1 |
20070239079 | Manstein et al. | Oct 2007 | A1 |
20070239142 | Altshuler et al. | Oct 2007 | A1 |
20080027328 | Klopotek et al. | Jan 2008 | A1 |
20080039724 | Seip et al. | Feb 2008 | A1 |
20080071255 | Barthe | Mar 2008 | A1 |
20080086054 | Slayton | Apr 2008 | A1 |
20080097253 | Pedersen | Apr 2008 | A1 |
20080139974 | Da Silva | Jun 2008 | A1 |
20080146970 | Litman et al. | Jun 2008 | A1 |
20080167556 | Thompson et al. | Jul 2008 | A1 |
20080183077 | Moreau-Gobard et al. | Jul 2008 | A1 |
20080188745 | Chen et al. | Aug 2008 | A1 |
20080195000 | Spooner et al. | Aug 2008 | A1 |
20080200810 | Buchalter | Aug 2008 | A1 |
20080200813 | Quistgaard | Aug 2008 | A1 |
20080214966 | Slayton | Sep 2008 | A1 |
20080221491 | Slayton | Sep 2008 | A1 |
20080223379 | Stuker et al. | Sep 2008 | A1 |
20080243035 | Crunkilton | Oct 2008 | A1 |
20080269608 | Anderson et al. | Oct 2008 | A1 |
20080275342 | Barthe | Nov 2008 | A1 |
20080281206 | Bartlett et al. | Nov 2008 | A1 |
20080281236 | Eshel et al. | Nov 2008 | A1 |
20080281237 | Slayton | Nov 2008 | A1 |
20080281255 | Slayton | Nov 2008 | A1 |
20080294073 | Barthe et al. | Nov 2008 | A1 |
20080319356 | Cain et al. | Dec 2008 | A1 |
20090005680 | Jones et al. | Jan 2009 | A1 |
20090012394 | Hobelsberger et al. | Jan 2009 | A1 |
20090043198 | Milner et al. | Feb 2009 | A1 |
20090043293 | Pankratov et al. | Feb 2009 | A1 |
20090069677 | Chen et al. | Mar 2009 | A1 |
20090093737 | Chomas et al. | Apr 2009 | A1 |
20090156969 | Santangelo | Jun 2009 | A1 |
20090171252 | Bockenstedt et al. | Jul 2009 | A1 |
20090177122 | Peterson | Jul 2009 | A1 |
20090177123 | Peterson | Jul 2009 | A1 |
20090182231 | Barthe et al. | Jul 2009 | A1 |
20090216159 | Slayton et al. | Aug 2009 | A1 |
20090226424 | Hsu | Sep 2009 | A1 |
20090227910 | Pedersen et al. | Sep 2009 | A1 |
20090253988 | Slayton et al. | Oct 2009 | A1 |
20090299175 | Bernstein et al. | Dec 2009 | A1 |
20090318909 | Debenedictis et al. | Dec 2009 | A1 |
20100011236 | Barthe et al. | Jan 2010 | A1 |
20100022919 | Peterson | Jan 2010 | A1 |
20100022922 | Barthe et al. | Jan 2010 | A1 |
20100042020 | Ben-Ezra | Feb 2010 | A1 |
20100049178 | Deem et al. | Feb 2010 | A1 |
20100063422 | Hynynen et al. | Mar 2010 | A1 |
20100130891 | Taggart et al. | May 2010 | A1 |
20100160782 | Slayton et al. | Jun 2010 | A1 |
20100160837 | Hunziker et al. | Jun 2010 | A1 |
20100168576 | Poland et al. | Jul 2010 | A1 |
20100191120 | Kraus et al. | Jul 2010 | A1 |
20100241035 | Barthe et al. | Sep 2010 | A1 |
20100280420 | Barthe et al. | Nov 2010 | A1 |
20100286518 | Lee et al. | Nov 2010 | A1 |
20110040171 | Foley et al. | Feb 2011 | A1 |
20110040190 | Jahnke et al. | Feb 2011 | A1 |
20110087099 | Eshel et al. | Apr 2011 | A1 |
20110087255 | Mccormack et al. | Apr 2011 | A1 |
20110112405 | Barthe et al. | May 2011 | A1 |
20110178444 | Slayton et al. | Jul 2011 | A1 |
20110190745 | Uebelhoer et al. | Aug 2011 | A1 |
20110264012 | Lautzenhiser et al. | Oct 2011 | A1 |
20120004549 | Barthe et al. | Jan 2012 | A1 |
20120016239 | Barthe et al. | Jan 2012 | A1 |
20120029353 | Slayton et al. | Feb 2012 | A1 |
20120035475 | Barthe et al. | Feb 2012 | A1 |
20120035476 | Barthe et al. | Feb 2012 | A1 |
20120046547 | Barthe et al. | Feb 2012 | A1 |
20120053458 | Barthe et al. | Mar 2012 | A1 |
20120111339 | Barthe et al. | May 2012 | A1 |
20120143056 | Slayton et al. | Jun 2012 | A1 |
20120165668 | Slayton et al. | Jun 2012 | A1 |
20120165848 | Slayton et al. | Jun 2012 | A1 |
20120197120 | Makin et al. | Aug 2012 | A1 |
20120197121 | Slayton et al. | Aug 2012 | A1 |
20120215105 | Slayton et al. | Aug 2012 | A1 |
20120271294 | Barthe et al. | Oct 2012 | A1 |
20120296240 | Azhari et al. | Nov 2012 | A1 |
20120316426 | Foley et al. | Dec 2012 | A1 |
20120330197 | Makin et al. | Dec 2012 | A1 |
20120330222 | Barthe et al. | Dec 2012 | A1 |
20120330223 | Makin et al. | Dec 2012 | A1 |
20130012755 | Slayton | Jan 2013 | A1 |
20130012816 | Slayton et al. | Jan 2013 | A1 |
20130012838 | Jaeger et al. | Jan 2013 | A1 |
20130012842 | Barthe | Jan 2013 | A1 |
20130018286 | Slayton et al. | Jan 2013 | A1 |
20130046209 | Slayton et al. | Feb 2013 | A1 |
20130066208 | Barthe et al. | Mar 2013 | A1 |
20130066237 | Smotrich et al. | Mar 2013 | A1 |
20130072826 | Slayton et al. | Mar 2013 | A1 |
20130096471 | Slayton et al. | Apr 2013 | A1 |
20130190659 | Slayton et al. | Jul 2013 | A1 |
20130211258 | Barthe et al. | Aug 2013 | A1 |
20130281853 | Slayton et al. | Oct 2013 | A1 |
20130281891 | Slayton et al. | Oct 2013 | A1 |
20130296697 | Slayton et al. | Nov 2013 | A1 |
20130296700 | Slayton et al. | Nov 2013 | A1 |
20130303904 | Barthe et al. | Nov 2013 | A1 |
20130303905 | Barthe et al. | Nov 2013 | A1 |
20130310863 | Barthe et al. | Nov 2013 | A1 |
20140082907 | Barthe | Mar 2014 | A1 |
20140142430 | Slayton et al. | May 2014 | A1 |
20140148834 | Barthe et al. | May 2014 | A1 |
20140180174 | Slayton et al. | Jun 2014 | A1 |
20140187944 | Slayton et al. | Jul 2014 | A1 |
20140188015 | Slayton et al. | Jul 2014 | A1 |
20140188145 | Slayton et al. | Jul 2014 | A1 |
Number | Date | Country |
---|---|---|
4029175 | Mar 1992 | DE |
10140064 | Mar 2003 | DE |
10219217 | Nov 2003 | DE |
10219297 | Nov 2003 | DE |
20314479 | Mar 2004 | DE |
0344773 | Dec 1989 | EP |
1479412 | Nov 1991 | EP |
0473553 | Mar 1992 | EP |
0661029 | Jul 1995 | EP |
1050322 | Nov 2000 | EP |
1234566 | Aug 2002 | EP |
1262160 | Dec 2002 | EP |
1374944 | Jan 2004 | EP |
2113099 | Aug 1983 | GB |
63036171 | Feb 1988 | JP |
03048299 | Mar 1991 | JP |
3123559 | May 1991 | JP |
03136642 | Jun 1991 | JP |
4089058 | Mar 1992 | JP |
04150847 | May 1992 | JP |
7080087 | Mar 1995 | JP |
07505793 | Jun 1995 | JP |
7222782 | Aug 1995 | JP |
09047458 | Feb 1997 | JP |
11505440 | May 1999 | JP |
11506636 | Jun 1999 | JP |
2000166940 | Jun 2000 | JP |
2001170068 | Jun 2001 | JP |
2002078764 | Mar 2002 | JP |
2002515786 | May 2002 | JP |
2002521118 | Jul 2002 | JP |
2002537939 | Nov 2002 | JP |
2003050298 | Feb 2003 | JP |
2003204982 | Jul 2003 | JP |
2004147719 | May 2004 | JP |
2005503388 | Feb 2005 | JP |
2005527336 | Sep 2005 | JP |
2005323213 | Nov 2005 | JP |
2006520247 | Sep 2006 | JP |
2007505793 | Mar 2007 | JP |
2009518126 | May 2009 | JP |
2010517695 | May 2010 | JP |
1020010024871 | Mar 2001 | KR |
100400870 | Oct 2003 | KR |
1020060113930 | Nov 2006 | KR |
1020070065332 | Jun 2007 | KR |
1020070070161 | Jul 2007 | KR |
1020070098856 | Oct 2007 | KR |
1020070104878 | Oct 2007 | KR |
1020070114105 | Nov 2007 | KR |
9625888 | Aug 1996 | WO |
9639079 | Dec 1996 | WO |
9735518 | Oct 1997 | WO |
9832379 | Jul 1998 | WO |
9933520 | Jul 1999 | WO |
9949788 | Oct 1999 | WO |
0006032 | Feb 2000 | WO |
0015300 | Mar 2000 | WO |
0021612 | Apr 2000 | WO |
0053113 | Sep 2000 | WO |
0128623 | Apr 2001 | WO |
0182777 | Nov 2001 | WO |
0182778 | Nov 2001 | WO |
0187161 | Nov 2001 | WO |
0209813 | Feb 2002 | WO |
0224050 | Mar 2002 | WO |
02092168 | Nov 2002 | WO |
020292168 | Nov 2002 | WO |
03053266 | Jul 2003 | WO |
03065347 | Aug 2003 | WO |
03070105 | Aug 2003 | WO |
03077833 | Aug 2003 | WO |
03086215 | Oct 2003 | WO |
03096883 | Nov 2003 | WO |
03099177 | Dec 2003 | WO |
03101530 | Dec 2003 | WO |
2004000116 | Dec 2003 | WO |
2004080147 | Sep 2004 | WO |
2004110558 | Dec 2004 | WO |
2005011804 | Feb 2005 | WO |
2005065408 | Jul 2005 | WO |
2005090978 | Sep 2005 | WO |
2006036870 | Apr 2006 | WO |
2006042163 | Apr 2006 | WO |
2006042168 | Apr 2006 | WO |
2006042201 | Apr 2006 | WO |
2006065671 | Jun 2006 | WO |
2006082573 | Aug 2006 | WO |
2007067563 | Jun 2007 | WO |
2008024923 | Feb 2008 | WO |
2008036622 | Mar 2008 | WO |
2009013729 | Jan 2009 | WO |
2009149390 | Dec 2009 | WO |
2014055708 | Apr 2014 | WO |
Entry |
---|
Sassen, Sander, “ATI's R520 architecture, the new king of the hill?” http://www.hardwareanalysis.com/content/article/1813, Sep. 16, 2005, 2 pages. |
Seip, Ralf, et al., “Noninvasive Detection of Thermal Effects Due to Highly Focused Ultrasonic Fiels,” IEEE Symposium, pp. 1229-1232, vol. 2, Oct. 3-Nov. 1993. |
Seip, Ralf, et al., “Noninvasive Estimation of Tissue Temperature Response to Heating Fields Using Diagnostic Ultrasound,” IEEE Transactions on Biomedical Engineering, vol. 42, No. 8, Aug. 1995, pp. 828-839. |
Simon et al., “Applications of Lipid-Coated Microbubble Ultrasonic Contrast to Tumor Therapy,” Ultrasound in Med & Biol. vol. 19, No. 2, pp. 123-125 (1993). |
Smith, Nadine Barrie, et al., “Non-Invasive In Vivo Temperature Mapping of Ultrasound Heating Using Magnetic Resonance Techniques”, 1994 Ultrasonics Symposium, pp. 1829-1832, vol. 3. |
Surry et al., “Poly(vinyl alcohol) cryogel phantoms for use in ultrasound and MR imaging,” Phys. Med. Biol., Dec. 6, 2004, pp. 5529-5546, vol. 49. |
Syka J. E. P. et al., “Peptide and Protein Sequence Analysis by Electron Transfer Dissociation Mass Spectometry,” Proceedings of the National Academy of Sciences of USA, National Academy of Aceince, Washington, DC, vol. 101, No. 26, Jun. 29, 2004, pp. 9528-9533. |
Talbert, D. G., “An Add-On Modification for Linear Array Real-Time Ultrasound Scanners to Produce 3D Displays,” UTS Int'l 1977 Brighton, England (Jun. 28-30, 1977) pp. 57-67. |
Tata et al., “Interaction of Ultrasound and Model Membrane Systems: Analyses and Predictions,” American Chemical Society, Phys. Chem. 1992, 96, pp. 3548-3555. |
Ueno, S., et al., “Ultrasound Thermometry in Hyperthermia”, 1990 Ultrasonic Symposium, pp. 1645-1652. |
Wang, H., et al., “Limits on Focused Ultrasound for Deep Hyperthermia”, 1994 Ultrasonic Symposium, Nov. 1-4, 1994, pp. 1869-1872, vol. 3. |
Wasson, Scott, “NVIDIA's GeFroce 7800 GTX graphics processor Power MADD,” http://techreport.com/reviews/2005q2/geforce-7800gtx/index.x?pg=1, Jun. 22, 2005, 4 pages. |
White et al “Selective Creation of Thermal Injury Zones in the Superficial Musculoaponeurotic System Using Intense Ultrasound Therapy,” Arch Facial Plastic Surgery, Jan./Feb. 2007, vol. 9, No. 1. |
Alster, Tinas S., Tanzi, Elizabeth L., “Cellulite Treatment using a Novel Combination Radiofrequency, Infrared Light, and Mechanical Tissue Manipulation Device,” Journal of Cosmetic & Laser Therapy, Jun. 2005, vol. 7, Issue 2, pp. 81-85. |
Arthur et al., “Non-invasive estimation of hyperthermia temperatures with ultrasound,” Int. J. Hyperthermia, Sep. 2005, 21(6), pp. 589-600. |
Barthe et al., “Ultrasound therapy system and abiation results utilizing miniature imaging/therapy arrays,” Ultrasonics Symposium, 2004 IEEE, Aug. 23, 2004, pp. 1792-1795, vol. 3. |
Calderhead et al, One Mechanism Behind LED Photo-Therapy for Wound Healing and Skin Rejuvenation: Key Role of the Mast Cell, Laser Therapy, Jul. 2008, pp. 141-148, 17.3. |
Chen, L. et al., “Effect of Blood Perfusion on the ablation of liver perenchyma with high intensity focused ultrasound,” Phys. Med. Biol; 38:1661-1673; 1993b. |
Coon, Joshua et al., “Protein identification using sequential ion/ion reactions and tandem mass spectometry” Proceedings of the National Academy of Sciences of the USA, vol. 102, No. 27, Jul. 5, 2005, pp. 9463-9468. |
European Examination Report in related Application No. 05808908.7 dated Jun. 29, 2009. |
European Examination Report in related Application No. 05810308.6 dated Jun. 29, 2009. |
European Examination Report in related Application No. 09835856.7 dated Apr. 11, 2004. |
European Examination Report in related Application No. 10185100.4 dated Jan. 6, 2014. |
European Examination Report in related Application No. 10185120.2 dated Jan. 22, 2014. |
Corry, Peter M., et al., “Human Cancer Treatment with Ultrasound”, IEEE Transactions on Sonics and Ultrasonics, vol. SU-31, No. 5, Sep. 1984, pp. 444,456. |
Damianou et al., Application of the Thermal Dose Concept for Predicting the Necrosed Tissue Volume During Ultrasound Surgery, 1993 IEEE Ultrasound Symposium, pp. 1199-1202. |
Daum et al., “Design and Evaluation of a Feedback Based Phased Array System for Ultrasound Surgery,” IEEE Transactions on Ultrasonics, Feroelectronics, and Frequency Control, vol. 45, No. 2, Mar. 1998, pp. 431-438. |
Davis, Brian J., et al., “An Acoustic Phase Shift Technique for the Non-Invasive Measurement of Temperature Changes in Tissues”, 1985 Ultrasonics Symposium, pp. 921-924. |
Decision of the Korean Intellectual Property Tribunal dated Jun. 28, 2013 regarding Korean Patent No. 10-1142108, which is related to the pending application and/or an application identified in the Table on the pp. 2-5 of the information Disclosure Statement herein (English translation, English translation certification, and Korean decision included). |
Fry, W.J. et al., “Production of Focal Destructive Lesions in the Central Nervous System with Ultrasound,” J. Neurosurg., 11:471-478; 1954. |
Gliklich et al., Clinical Pilot Study of Intense Ultrasound therapy to Deep Dermal Facial Skin and Subcutaneous Tissues, Arch Facial Plastic Surgery, Mar. 1, 2007, vol. 9. |
Harr, G.R. et al., “Tissue Destruction with Focused Ultrasound in Vivo,” Eur. Urol. 23 (suppl. 1):8-11; 1993. |
Hassan et al., “Structure and Applications of Poly(vinyl alcohol) Hydrogels Produced by Conventional Crosslinking or by Freezing/Thawing Methods,” advanced in Polymer Science, 2000, pp. 37-65, vol. 153. |
Hassan et al., “Structure and Morphology of Freeze/Thawed PVA Hydrogels,” Macromolecules, Mar. 11, 2000, pp. 2472-2479, vol. 33, No. 7. |
Husseini et al, “The Role of Cavitation in Acoustically Activated Drug Delivery,” J. Control Release, Oct. 3, 2005, pp. 253-261, vol. 107(2). |
Husseini et al. “Investigating the mechanism of accoustically activated uptake of drugs from Pluronic micelles,” BMD Cancer 2002, 2:20k, Aug. 30, 2002, pp. 1-6. |
International Search Report and Written Opinion dated Jan. 23, 2014 in Application No. PCT/US2012/046122. |
International Search Report and Written Opinion dated Jan. 23, 2014 in Application No. PCT/US2012/046123. |
International Search Report and Written Opinion dated Jan. 28, 2012 in Application No. PCT/US2012/046327. |
International Search Report and Written Opinion dated Jan. 28, 2013 in Application No. PCT/US2012/046125. |
International Search Report and Written Opinion dated Feb. 14, 2013 in Application No. PCT/US2011/001361. |
International Search Report and Written Opinion dated Feb. 14, 2013 in Application No. PCT/US2011/001362. |
International Search Report and Written Opinion dated Feb. 14, 2013 in Application No. PCT/US2011/001366. |
International Search Report and Written Opinion dated Apr. 6, 2012 in Application No. PCT/US2011/001366. |
International Search Report and Written Opinion dated Apr. 6, 2012 in Application No. PCT/US2011/001367. |
Jeffers et al., “Evaluation of the Effect of Cavitation Activity on Drug-Ultrasound Synergisms,” 1993 IEEE Ultrasonics Symposium, pp. 925-928. |
Jenne, J., et al., “Temperature Mapping for High Energy US-Therapy”, 1994 Ultrasonics Symposium, pp. 1879-1882. |
Johnson, S.A., et al., “Non-Intrusive Measurement of Microwave and Ultrasound-Induced Hyperthermia by Acoustic temperature Tomography”, Ultrasonics Symposium Proceedings, pp. 977-982. |
Madersbacher, S. et al., “Tissue Ablation in Bening Prostatic Hyperplasia with High Intensity Focused Ultrasound,” Dur. Urol., 23 (suppl. 1):39-43; 1993. |
Makin et al, “B-Scan Imaging and Thermal Lesion Monitoring Using Miniaturized Dual-Functionality Ultrasound Arrays,” Ultrasonics Symposium, 2004 IEEE, Aug. 23, 2004, pp. 1788-1791, vol. 3. |
Makin et al, “Miniaturized Ultrasound Arrays for Interstitial Ablation and Imaging,” UltraSound Med. Biol. 2005, Nov. 1, 2005, pp. 1539-1550, vol. 31(11). |
Makin et al., “Confirmal Bulk Ablation and Therapy Monitoring Using Intracorporeal Image-Treat Ultrasound Arrays”, 4th International Symposium on Therapeutic Ultrasound, Sep. 19, 2004. |
Manohar et al, “Photoaccoustic mammography laboratory prototype: imaging of breast tissue phantoms,” Journal of Biomedical Optics, Nov./Dec. 2004, pp. 1172-1181, vol. 9, No. 6. |
Mast et al, “Bulk Ablation of Soft Tissue with Intense Ultrasound; Modeling nad Experiments,” J. Acoust. Soc. Am., Oct. 1, 2005, pp. 2715-2724, vol. 118(4). |
Mitragotri, Samir; “Healing sound: the use of ultrasound in drug delivery and other therapeutic applications,” Nature Reviews; Drug Delivery, pp. 255-260, vol. 4. |
Paradossi et al., “Poly(vinyl alcohol) as versatile biomaterial for potential biomedical applications,” Journal of Materials Science: Materials in Medicine, 2003, pp. 687-691, vol. 14. |
PCT/US2012/046122 International Search Report Jan. 30, 2013. |
PCT/US2012/046123 International Search Report Jan. 28, 2013. |
PCT/US2012/046125 International Search Report Jan. 28, 2013. |
Reid, Gavin, et al., “Tandem Mass spectrometry of ribonuclease A and B: N-linked glycosylation site analysis of whole protein ions,” Analytical Chemistry. Feb. 1, 2002, vol. 74, No. 3, pp. 577-583. |
Righetti et al, “Elastographic Characterization of HIFU-Induced Lesions in Canine Livers,” 1999, Ultrasound in Med & Bio, vol. 25, No. 7, pp. 1099-1113. |
Saad et al., “Ultrasound-Enhanced Effects of Adriamycin Against Murine Tumors,” Ultrasound in Med. & Biol. vol. 18, No. 8, pp. 715-723 (1992). |
Sanghvi, N.T., et al., “Transrectal Ablation of Prostrate Tissue Using Focused Ultrasound,” 1993 Ultrasonics Symposium, IEEE, pp. 1207-1210. |
PCT International Search Report and Written Opinion, PCT/US2014/030779, Sep. 1, 2014, 8 pages. |
European Patent Office, Examination Report, EP 07814933.3, Aug. 5, 2014, 5 pages. |
European Patent Office, Examination Report, EP 05798870.1, Oct. 20, 2014, 5 pages. |
European Patent Office, Examination Report, EP 10185100.4, Oct. 24, 2014, 4 pages. |
European Patent Office, Examination Report, EP 10185112.9, Oct. 24, 2014, 5 pages. |
European Patent Office, Examination Report, EP 10185117.8, Oct. 24, 2014, 5 pages. |
European Patent Office, Examination Report, EP 10185120.2, Oct. 24, 2014, 4 pages. |
Number | Date | Country | |
---|---|---|---|
20140243713 A1 | Aug 2014 | US |
Number | Date | Country | |
---|---|---|---|
61263916 | Nov 2009 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 12954484 | Nov 2010 | US |
Child | 14270859 | US |